KURA ONCOLOGY, INC. Accounts Payable and Other Accrued Liabilities, Current
KURA ONCOLOGY, INC. (KURA) had Accounts Payable and Other Accrued Liabilities, Current of $1.40 million as of 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2022-08-03
- 2022-06-30: Accounts Payable and Other Accrued Liabilities, Current $1.40M.
- 2021-12-31: Accounts Payable and Other Accrued Liabilities, Current $4.31M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2022-06-30 | $1.40M 10-Q · filed 2022-08-03 |
| 2021-12-31 | $4.31M 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |